Arbutus Biopharma Corp Stock Filter Stocks by Fundamentals
| ABUS Stock | USD 3.33 0.03 0.91% |
Arbutus Biopharma Corp fundamentals help investors to digest information that contributes to Arbutus Biopharma's financial success or failures. It also enables traders to predict the movement of Arbutus Stock. The fundamental analysis module provides a way to measure Arbutus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arbutus Biopharma stock.
Arbutus | Shares Owned by Insiders |
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 269.2M | 413.3M | 351.7M | 414.9M | 373.4M | 392.1M | |
| Enterprise Value | 219.9M | 306.6M | 323.1M | 397.3M | 357.6M | 375.5M |
Arbutus Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arbutus Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arbutus Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Arbutus Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Arbutus Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arbutus Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arbutus Biopharma's value.| Shares | Rubric Capital Management Lp | 2024-09-30 | 1.7 M | Advisor Group Holdings, Inc. | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Hudson Bay Capital Management Lp | 2024-09-30 | 1 M | Corbin Capital Partners Lp | 2024-09-30 | 853.3 K | Saba Capital Management, Lp | 2024-09-30 | 676.4 K | Woodline Partners Lp | 2024-09-30 | 668.2 K | Boothbay Fund Management, Llc | 2024-09-30 | 612.3 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 21.7 M | Whitefort Capital Management, Lp. | 2024-09-30 | 12.9 M |
Arbutus Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 498.97 M | ||||
| Shares Outstanding | 189.49 M | ||||
| Shares Owned By Insiders | 22.22 % | ||||
| Shares Owned By Institutions | 53.85 % | ||||
| Number Of Shares Shorted | 6.64 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 5.85 X | ||||
| Price To Sales | 92.75 X | ||||
| Revenue | 18.14 M | ||||
| Gross Profit | (56.05 M) | ||||
| EBITDA | (70.99 M) | ||||
| Net Income | (72.85 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 8.72 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (85.94 M) | ||||
| Short Ratio | 7.07 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 5.11 | ||||
| Number Of Employees | 73 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 625.32 M | ||||
| Total Asset | 144.4 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 109.54 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.